Brokerages Set Solventum Co. (NYSE:SOLV) Price Target at $74.71

Shares of Solventum Co. (NYSE:SOLV) have earned an average rating of “Hold” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $79.86.

A number of equities research analysts have recently issued reports on SOLV shares. Piper Sandler boosted their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Finally, Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th.

Solventum Stock Up 2.9 %

Shares of Solventum stock opened at $77.96 on Friday. The stock’s fifty day moving average is $73.65 and its 200-day moving average is $70.55. The firm has a market capitalization of $13.47 billion and a PE ratio of 28.35. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum has a 12-month low of $47.16 and a 12-month high of $85.92.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. New York Life Investment Management LLC grew its stake in Solventum by 0.7% in the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock valued at $1,223,000 after purchasing an additional 136 shares in the last quarter. Blue Trust Inc. grew its stake in Solventum by 2.1% in the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after purchasing an additional 161 shares in the last quarter. MML Investors Services LLC boosted its stake in shares of Solventum by 3.2% during the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after acquiring an additional 168 shares in the last quarter. EP Wealth Advisors LLC boosted its stake in shares of Solventum by 3.6% during the 4th quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company’s stock worth $348,000 after acquiring an additional 181 shares in the last quarter. Finally, Avantax Advisory Services Inc. boosted its stake in shares of Solventum by 2.2% during the 4th quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after acquiring an additional 192 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.